Novartis Transderm Scop relaunch to include mailing to consumers who called while product was unavailable.
NOVARTIS TRANSDERM SCOP RE-LAUNCH WILL BEGIN WITH DIRECT MAIL campaign to health care professionals in September. The campaign will be directed to a database of callers who previously contacted Novartis' toll-free number requesting the scopolamine 1.5 mg patch for motion sickness. Direct mailings to consumers in the database will follow in November. The patch will be promoted by Novartis' consumer products division.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth